Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Aesthetic Expansion | Evolus enters the hyaluronic acid dermal filler market with FDA-approved Evolysse, potentially increasing its addressable market by 78% to $6 billion |
Financial Milestones | Explore Evolus's journey to profitability, with Q3 2024 revenue of $61 million and ambitious targets of $700 million revenue by 2028 |
Market Dynamics | Delve into the "Ozempic effect" driving filler demand and how Evolus's cold cross-linking technology positions it against established competitors |
Growth Trajectory | Analysts project $16-$27 price targets, with fillers expected to contribute 8-10% of 2025 revenue, signaling potential for significant market expansion |
Metrics to compare | EOLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEOLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | 10.3x | −0.5x | |
PEG Ratio | −4.73 | 0.43 | 0.00 | |
Price/Book | −15.6x | 1.3x | 2.6x | |
Price / LTM Sales | 1.2x | 2.0x | 3.2x | |
Upside (Analyst Target) | 153.2% | 45.8% | 51.4% | |
Fair Value Upside | Unlock | 38.1% | 8.5% | Unlock |